{"id":"qiv","rwe":[],"tags":[],"safety":{"safetySignals":[{"date":"","signal":"SINUSITIS","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"TREMOR","source":"FDA FAERS","actionTaken":"Reported 1 times"}],"drugInteractions":[{"drug":"Live, inactivated influenza vaccine","action":"Avoid","effect":"Decreased immune response"},{"drug":"Live attenuated influenza vaccine","action":"Avoid","effect":"Decreased immune response"},{"drug":"Other vaccines","action":"Avoid","effect":"Decreased immune response"},{"drug":"Immunoglobulin","action":"Avoid","effect":"Decreased immune response"},{"drug":"Thrombolytic agents","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Anticoagulants","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet agents","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"NSAIDs","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Heparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabigatran","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Rivaroxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Apixaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Edoxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Fondaparinux","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bivalirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Argatroban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Desirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Lepirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bleomycin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Doxorubicin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Daunorubicin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Idarubicin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Mitomycin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Plicamycin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Trastuzumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bevacizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Ramucirumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aflibercept","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Cetuximab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Panitumumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Regorafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Sorafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Sunitinib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tensirolimus","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Everolimus","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Sirolimus","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Temsirolimus","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Vandetanib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Cabozantinib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Crizotinib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Neratinib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pazopanib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Sorafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Sunitinib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tivozanib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Vemurafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabrafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Encorafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pazopanib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Regorafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Sorafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Sunitinib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tivozanib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Vemurafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabrafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Encorafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pazopanib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Regorafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Sorafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Sunitinib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tivozanib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Vemurafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabrafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Encorafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pazopanib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Regorafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Sorafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Sunitinib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tivozanib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Vemurafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabrafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Encorafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pazopanib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Regorafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Sorafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Sunitinib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tivozanib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Vemurafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabrafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Encorafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pazopanib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Regorafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Sorafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Sunitinib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tivozanib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Vemurafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabrafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Encorafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pazopanib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Regorafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Sorafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Sunitinib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tivozanib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Vemurafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabrafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Encorafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pazopanib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Regorafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Sorafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Sunitinib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tivozanib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Vemurafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabrafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Encorafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pazopanib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Regorafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Sorafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Sunitinib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tivozanib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Vemurafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabrafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Encorafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pazopanib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Regorafenib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Sorafenib","action":"Monitor","effect":"Increased risk of bleeding"}],"commonSideEffects":[{"effect":"Pain","drugRate":"19.3%","placeboRate":"","totalAtRisk":13869,"totalAffected":2676,"trialsReporting":4},{"effect":"Irritability","drugRate":"22.0%","placeboRate":"","totalAtRisk":9761,"totalAffected":2146,"trialsReporting":3},{"effect":"Injection site pain (PAIN)","drugRate":"23.0%","placeboRate":"","totalAtRisk":9191,"totalAffected":2112,"trialsReporting":1},{"effect":"Fatigue (FATIGUE)","drugRate":"17.2%","placeboRate":"","totalAtRisk":9191,"totalAffected":1579,"trialsReporting":1},{"effect":"Somnolence","drugRate":"17.4%","placeboRate":"","totalAtRisk":8862,"totalAffected":1539,"trialsReporting":2},{"effect":"Nasopharyngitis","drugRate":"8.4%","placeboRate":"","totalAtRisk":16510,"totalAffected":1395,"trialsReporting":4},{"effect":"Headache (HEADACHE)","drugRate":"13.9%","placeboRate":"","totalAtRisk":9191,"totalAffected":1273,"trialsReporting":1},{"effect":"Decreased appetite","drugRate":"11.1%","placeboRate":"","totalAtRisk":11070,"totalAffected":1233,"trialsReporting":2},{"effect":"Upper respiratory tract infection","drugRate":"8.8%","placeboRate":"","totalAtRisk":13926,"totalAffected":1224,"trialsReporting":3},{"effect":"Erythema","drugRate":"8.6%","placeboRate":"","totalAtRisk":13894,"totalAffected":1198,"trialsReporting":4},{"effect":"Pyrexia","drugRate":"8.5%","placeboRate":"","totalAtRisk":13926,"totalAffected":1184,"trialsReporting":3},{"effect":"Injection site pain","drugRate":"5.8%","placeboRate":"","totalAtRisk":17111,"totalAffected":987,"trialsReporting":3},{"effect":"Myalgia (MUSCLE PAIN)","drugRate":"10.0%","placeboRate":"","totalAtRisk":9191,"totalAffected":920,"trialsReporting":1},{"effect":"Swelling","drugRate":"6.2%","placeboRate":"","totalAtRisk":13676,"totalAffected":847,"trialsReporting":3},{"effect":"Pain at injection site","drugRate":"30.2%","placeboRate":"","totalAtRisk":2606,"totalAffected":788,"trialsReporting":1},{"effect":"Chills (CHILLS)","drugRate":"8.0%","placeboRate":"","totalAtRisk":9191,"totalAffected":731,"trialsReporting":1},{"effect":"Injection site erythema","drugRate":"9.1%","placeboRate":"","totalAtRisk":7920,"totalAffected":720,"trialsReporting":2},{"effect":"Headache","drugRate":"7.3%","placeboRate":"","totalAtRisk":9479,"totalAffected":691,"trialsReporting":4},{"effect":"Myalgia","drugRate":"6.7%","placeboRate":"","totalAtRisk":7804,"totalAffected":524,"trialsReporting":3},{"effect":"Arthralgia (JOINT PAIN)","drugRate":"5.4%","placeboRate":"","totalAtRisk":9191,"totalAffected":493,"trialsReporting":1},{"effect":"Injection site induration","drugRate":"16.2%","placeboRate":"","totalAtRisk":2856,"totalAffected":464,"trialsReporting":1},{"effect":"Eating disorder","drugRate":"15.7%","placeboRate":"","totalAtRisk":2856,"totalAffected":447,"trialsReporting":1},{"effect":"Diarrhoea","drugRate":"4.9%","placeboRate":"","totalAtRisk":7920,"totalAffected":386,"trialsReporting":2},{"effect":"Diarrhoea (DIARRHEA)","drugRate":"3.9%","placeboRate":"","totalAtRisk":9191,"totalAffected":355,"trialsReporting":1},{"effect":"Rhinitis","drugRate":"4.0%","placeboRate":"","totalAtRisk":7920,"totalAffected":313,"trialsReporting":2},{"effect":"Injection site bruising","drugRate":"3.8%","placeboRate":"","totalAtRisk":7920,"totalAffected":304,"trialsReporting":2},{"effect":"Overall Discomfort","drugRate":"11.1%","placeboRate":"","totalAtRisk":2606,"totalAffected":290,"trialsReporting":1},{"effect":"Fatigue","drugRate":"4.1%","placeboRate":"","totalAtRisk":6895,"totalAffected":283,"trialsReporting":3},{"effect":"Muscle aches","drugRate":"15.6%","placeboRate":"","totalAtRisk":1648,"totalAffected":257,"trialsReporting":1},{"effect":"Injection site swelling (SWELLING)","drugRate":"2.8%","placeboRate":"","totalAtRisk":9191,"totalAffected":254,"trialsReporting":1},{"effect":"Injection site erythema (REDNESS)","drugRate":"2.5%","placeboRate":"","totalAtRisk":9191,"totalAffected":230,"trialsReporting":1},{"effect":"Vomiting","drugRate":"2.5%","placeboRate":"","totalAtRisk":7920,"totalAffected":201,"trialsReporting":2},{"effect":"Cough","drugRate":"2.4%","placeboRate":"","totalAtRisk":7648,"totalAffected":184,"trialsReporting":2},{"effect":"Pyrexia (FEVER)","drugRate":"1.8%","placeboRate":"","totalAtRisk":9191,"totalAffected":170,"trialsReporting":1},{"effect":"Respiratory tract infection","drugRate":"2.1%","placeboRate":"","totalAtRisk":7920,"totalAffected":170,"trialsReporting":2},{"effect":"Joint pain","drugRate":"8.7%","placeboRate":"","totalAtRisk":1648,"totalAffected":143,"trialsReporting":1},{"effect":"Gastro.","drugRate":"8.1%","placeboRate":"","totalAtRisk":1648,"totalAffected":133,"trialsReporting":1},{"effect":"Loss of appetite","drugRate":"13.2%","placeboRate":"","totalAtRisk":899,"totalAffected":119,"trialsReporting":1},{"effect":"Drowsiness","drugRate":"11.1%","placeboRate":"","totalAtRisk":899,"totalAffected":100,"trialsReporting":1},{"effect":"Influenza like illness","drugRate":"1.6%","placeboRate":"","totalAtRisk":5064,"totalAffected":82,"trialsReporting":1},{"effect":"Temperature","drugRate":"8.2%","placeboRate":"","totalAtRisk":899,"totalAffected":74,"trialsReporting":1},{"effect":"Induration","drugRate":"32.3%","placeboRate":"","totalAtRisk":201,"totalAffected":65,"trialsReporting":1},{"effect":"Arthralgia","drugRate":"1.2%","placeboRate":"","totalAtRisk":5202,"totalAffected":64,"trialsReporting":2},{"effect":"Oropharyngeal pain","drugRate":"1.1%","placeboRate":"","totalAtRisk":5064,"totalAffected":54,"trialsReporting":1},{"effect":"Nasal congestion","drugRate":"1.0%","placeboRate":"","totalAtRisk":5064,"totalAffected":49,"trialsReporting":1},{"effect":"Rhinorrhoea","drugRate":"0.8%","placeboRate":"","totalAtRisk":5064,"totalAffected":40,"trialsReporting":1},{"effect":"Sneezing","drugRate":"0.5%","placeboRate":"","totalAtRisk":5064,"totalAffected":26,"trialsReporting":1},{"effect":"Sinusitis","drugRate":"0.5%","placeboRate":"","totalAtRisk":5064,"totalAffected":24,"trialsReporting":1},{"effect":"Respiratory disorder","drugRate":"0.5%","placeboRate":"","totalAtRisk":5064,"totalAffected":24,"trialsReporting":1},{"effect":"Back pain","drugRate":"0.4%","placeboRate":"","totalAtRisk":5064,"totalAffected":22,"trialsReporting":1}],"contraindications":["a history of severe allergic reaction to a vaccine component (except egg) or after a previous dose of any influenza vaccine (people with egg allergy of any severity may receive LAIV if it is otherwise appropriate for their age and health status)","concomitant aspirin- or salicylate-containing therapy in children and adolescents because of the risk of Reye syndrome","children age 2 through 4 years who have received a diagnosis of asthma or whose parents or caregivers report that a child has asthma","immunosuppression due to any cause, including medications, congenital or acquired immunodeficiency states, HIV infection, anatomic asplenia or functional asplenia (e.g., due to sickle cell anemia)","cranial cerebral spinal fluid (CSF) leak or cochlear implant (due to potential for CSF leak)","close contacts and caregivers of severely immunosuppressed people who require a protected environment","pregnancy","receipt of influenza antiviral medication within the previous 48 hours (for oseltamivir or zanamivir), previous 5 days (for peramivir), or previous 17 days (for baloxavir)"],"specialPopulations":{"Pregnancy":"See section 8.1 for specific guidance.","Geriatric use":"In patients over 65 years of age, do not exceed the recommended dose. Patients are at higher risk for thrombosis and renal dysfunction.","Paediatric use":"See section 8.4 for specific guidance.","Renal impairment":"Renal dysfunction, acute renal failure, osmotic nephrosis may occur with immune globulin intravenous (IGIV) products. Patients predisposed to renal dysfunction include those with any degree of pre-existing renal insufficiency, diabetes mellitus. Ensure adequate hydration and consider the minimum dose and infusion rate for patients at risk.","Hepatic impairment":"No specific guidance provided."}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=qiv","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:38:40.240115+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:38:46.023909+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:38:40.307626+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=qiv","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:38:46.208931+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"6f1933e0-240f-48f4-b246-8a30e63a4160","title":"QIVIGY KTHM (HUMAN IMMUNOGLOBULIN G) INJECTION, SOLUTION [KEDRION S.P.A.]","labeler":""},"aiSummary":"Pfizer's QIV is a marketed influenza vaccine preventing A(H1N1)pdm09, A(H3N2), and influenza B viruses. It has 100 trials and 302 publications. The vaccine generated $62.6B in revenue. QIV's mechanism involves preventing influenza viruses from infecting cells. This is crucial for preventing influenza-related complications. QIV's commercial significance lies in its widespread use during flu seasons. Pfizer continues to develop its pipeline, including updates to QIV.","brandName":"Qiv","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Influenza viruses","novelty":"Best-in-class","modality":"Vaccine","drugClass":"Inactivated vaccine","explanation":"","oneSentence":"","technicalDetail":"QIV is a quadrivalent influenza vaccine that contains inactivated viruses from four different strains of the flu. The vaccine is administered via injection and stimulates the production of antibodies that help neutralize the virus. This provides long-term protection against influenza-related illnesses."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"-2%","annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"","patientPopulation":"Generic — multiple manufacturers","peakSalesEstimate":"$21.2B"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=qiv","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=qiv","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://open.fda.gov/apis/drug/event/","fields":["safetySignals"],"source":"FDA FAERS"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:28:14.321330+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Gammagard Liquid","company":"Brand Names include: Gammagard Liquid ERC, Gammaked, Gamunex-C","advantage":"Used for Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Primary Immunodeficiency Syndrome, and Motor Neuropathy"},{"name":"Hizentra","company":"Brand Names include: Hizentra","advantage":"Used for Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Primary Immunodeficiency Syndrome"},{"name":"Panzyga","company":"Brand Names include: Panzyga","advantage":"Used for Primary Immunodeficiency Syndrome"},{"name":"Hyqvia","company":"Brand Names include: Hyqvia","advantage":"Used for Primary Immunodeficiency Syndrome"},{"name":"Privigen","company":"Brand Names include: Privigen","advantage":"Used for Primary Immunodeficiency Syndrome"},{"name":"Gamunex-C","company":"Brand Names include: Gamunex-C","advantage":"Used for Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Primary Immunodeficiency Syndrome"},{"name":"Gammagard S/D","company":"Brand Names include: Gammagard S/D","advantage":"Used for Primary Immunodeficiency Syndrome"},{"name":"Gammaplex","company":"Brand Names include: Gammaplex","advantage":"Used for Primary Immunodeficiency Syndrome"},{"name":"Octagam","company":"Brand Names include: Octagam","advantage":"Used for Primary Immunodeficiency Syndrome"},{"name":"Alyglo","company":"Brand Names include: Alyglo","advantage":"Used for Primary Immunodeficiency Syndrome"},{"name":"Asceniv","company":"Brand Names include: Asceniv","advantage":"Used for Primary Immunodeficiency Syndrome"},{"name":"Bivigam","company":"Brand Names include: Bivigam","advantage":"Used for Primary Immunodeficiency Syndrome"},{"name":"Carimune NF","company":"Brand Names include: Carimune NF","advantage":"Used for Primary Immunodeficiency Syndrome"},{"name":"Flebogamma","company":"Brand Names include: Flebogamma","advantage":"Used for Primary Immunodeficiency Syndrome"},{"name":"Cutaquig","company":"Brand Names include: Cutaquig","advantage":"Used for Primary Immunodeficiency Syndrome"},{"name":"Yimmugo","company":"Brand Names include: Yimmugo","advantage":"Used for Primary Immunodeficiency Syndrome"}],"genericName":"qiv","indications":{"approved":[{"name":"Influenza prevention","regulator":"FDA"},{"name":"Prevention of influenza A virus, A(H1N1)pdm09, A(H3N2), and influenza B viruses","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_drugWebsite":{"url":"https://www.qiv.com","content":"qiv.com\n\nThis domain is for sale!\n\nListed by Red Penguin\nOwn this domain\n\nThis domain can be yours today.\n\nInternational\nAfghanistan\nÅland Islands\nAlbania\nAlgeria\nAmerican Samoa\nAndorra\nAngola\nAnguilla\nAntigua and Barbuda\nArgentina\nArmenia\nAruba\nAscension Island\nAustralia\nAustria\nAzerbaijan\nBahamas\nBahrain\nBangladesh\nBarbados\nBelarus\nBelgium\nBelize\nBenin\nBermuda\nBhutan\nBolivia\nBonaire, Sint Eustatius and Saba\nBosnia and Herzegovina\nBotswana\nBrazil\nBritish Indian Ocean Territory\nBrunei Darussalam\nBulgaria\nBurkina Faso\nBurundi\nCambodia\nCameroon\nCanada\nCape Verde\nCayman Islands\nCentral African Republic\nChad\nChile\nChina\nChristmas Island\nCocos (Keeling) Islands\nColombia\nComoros\nCongo\nCongo, Democratic Republic of the\nCook Islands\nCosta Rica\nCote d'Ivoire\nCroatia\nCuba\nCuraçao\nCyprus\nCzech Republic\nDenmark\nDjibouti\nDominica\nDominican Republic\nEcuador\nEgypt\nEl Salvador\nEquatorial Guinea\nEritrea\nEstonia\nEthiopia\nFalkland Islands\nFaroe Islands\nFederated States of Micronesia\nFiji\nFinland\nFrance\nFrench Guiana\nFrench Polynesia\nGabon\nGambia\nGeorgia\nGermany\nGhana\nGibraltar\nGreece\nGreenland\nGrenada\nGuadeloupe\nGuam\nGuatemala\nGuernsey\nGuinea\nGuinea-Bissau\nGuyana\nHaiti\nHoly See (Vatican City State)\nHonduras\nHong Kong\nHungary\nIceland\nIndia\nIndonesia\nIran\nIraq\nIreland\nIsle of Man\nIsrael\nItaly\nJamaica\nJapan\nJersey\nJordan\nKazakhstan\nKenya\nKiribati\nKosovo\nKuwait\nKyrgyzstan\nLaos\nLatvia\nLebanon\nLesotho\nLiberia\nLibya\nLiechtenstein\nLithuania\nLuxembourg\nMacao\nMadagascar\nMalawi\nMalaysia\nMaldives\nMali\nMalta\nMarshall Islands\nMartinique\nMauritania\nMauritius\nMayotte\nMexico\nMoldova\nMonaco\nMongolia\nMontenegro\nMontserrat\nMorocco\nMozambique\nMyanmar\nNamibia\nNauru\nNepal\nNetherlands\nNew Caledonia\nNew Zealand\nNicaragua\nNiger\nNigeria\nNiue\nNorfolk Island\nNorth Korea\nNorth Macedonia\nNorthern Mariana Islands\nNorway\nOman\nPakistan\nPalau\nPalestine\nPanama\nPapua New Guinea\nParaguay\nPeru\nPhilippines\nPoland\nPortugal\nPuerto Rico\nQatar\nReunion\nRomania\nRussia\nRwanda\nSaint Barthélemy\nSaint Helena\nSaint Kitts and Nevis\nSai"},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07485855","phase":"PHASE3","title":"Influenza Vaccination Strategy for Patients With Hematologic Malignancy","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-12-04","conditions":"Hematologic Neoplasms, Influenza, Immunogenicity","enrollment":60},{"nctId":"NCT05945485","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-16","conditions":"Influenza","enrollment":50},{"nctId":"NCT05227001","phase":"PHASE1","title":"A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-04-28","conditions":"Influenza, Human","enrollment":440},{"nctId":"NCT06087640","phase":"PHASE3","title":"A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seqirus","startDate":"2023-10-23","conditions":"Influenza, Human","enrollment":35800},{"nctId":"NCT06431607","phase":"PHASE2","title":"A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-05-23","conditions":"Influenza, Human","enrollment":845},{"nctId":"NCT04697576","phase":"PHASE1","title":"Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma","status":"RECRUITING","sponsor":"Carlo Contreras","startDate":"2021-10-20","conditions":"Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8","enrollment":36},{"nctId":"NCT03650114","phase":"PHASE3","title":"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-28","conditions":"Relapsing Multiple Sclerosis","enrollment":1882},{"nctId":"NCT05294588","phase":"PHASE2","title":"Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-04-18","conditions":"Gonorrhea Male","enrollment":65},{"nctId":"NCT03501576","phase":"","title":"Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma","status":"RECRUITING","sponsor":"Emory University","startDate":"2018-04-06","conditions":"Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":200},{"nctId":"NCT05108818","phase":"PHASE4","title":"Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2021-10-07","conditions":"Influenza, Human","enrollment":700},{"nctId":"NCT07211152","phase":"PHASE3","title":"Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-10-13","conditions":"Influenza","enrollment":150},{"nctId":"NCT07357467","phase":"","title":"Effect of Oral Supplement on Influenza Vaccine Long-term Response","status":"NOT_YET_RECRUITING","sponsor":"Tsinghua University","startDate":"2026-03","conditions":"Influenza, Immunosenescence","enrollment":30},{"nctId":"NCT04613206","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-01-11","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":396},{"nctId":"NCT06503900","phase":"PHASE4","title":"Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study","status":"COMPLETED","sponsor":"Duke University","startDate":"2024-09-12","conditions":"Birth Outcomes, Safety, Adverse Event Following Immunization","enrollment":98},{"nctId":"NCT06024096","phase":"PHASE4","title":"Systems Biological Assessment of Statin Effect on Vaccine Responses","status":"COMPLETED","sponsor":"Emory University","startDate":"2023-09-20","conditions":"Vaccine Response","enrollment":63},{"nctId":"NCT06436703","phase":"PHASE2","title":"A Study About Modified RNA Vaccines Against Influenza in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-05-23","conditions":"Influenza, Human","enrollment":1202},{"nctId":"NCT04544267","phase":"PHASE3","title":"Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-09-15","conditions":"Influenza","enrollment":100},{"nctId":"NCT06694025","phase":"","title":"Post-marketing Surveillance Study for the Safety of Efluelda Tetra Pre-filled Syringe.","status":"NOT_YET_RECRUITING","sponsor":"Sanofi","startDate":"2026-10-01","conditions":"Immunization, Influenza (Healthy Volunteers)","enrollment":670},{"nctId":"NCT05215327","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2022-11-08","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":270},{"nctId":"NCT06831786","phase":"EARLY_PHASE1","title":"Immunogenicity of COVID-19 Vaccine Co-administration With Influenza Vaccine in Healthy Volunteers","status":"COMPLETED","sponsor":"Prince of Songkla University","startDate":"2024-03-01","conditions":"COVID - 19","enrollment":36},{"nctId":"NCT05606965","phase":"PHASE2","title":"A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-11-02","conditions":"Influenza","enrollment":172},{"nctId":"NCT06508437","phase":"PHASE4","title":"Effect of Influenza Vaccination on Global Systemic Inflammatory Markers in Patients With Stable Coronary Artery Disease","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2024-10-21","conditions":"Coronary Artery Disease, Inflammatory Response, Atherosclerosis","enrollment":47},{"nctId":"NCT06824519","phase":"PHASE1, PHASE2","title":"Clinical Trials of Quadrivalent Influenza Vaccine","status":"RECRUITING","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2025-05-08","conditions":"Influenza, Human","enrollment":620},{"nctId":"NCT05479370","phase":"PHASE3","title":"Immunogenicity Trial of 3 Influenza Vaccines","status":"COMPLETED","sponsor":"Tan Tock Seng Hospital","startDate":"2022-09-29","conditions":"Influenza Vaccination","enrollment":366},{"nctId":"NCT05755620","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-04-05","conditions":"Influenza","enrollment":50},{"nctId":"NCT05526716","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-09-23","conditions":"Pneumonia, Pneumococcal","enrollment":1080},{"nctId":"NCT03945825","phase":"PHASE1","title":"Flublok or Fluzone With Advax-CpG55.2 or AF03","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-06-10","conditions":"Influenza, Influenza Immunisation","enrollment":241},{"nctId":"NCT04537234","phase":"PHASE3","title":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-11-10","conditions":"Influenza (Healthy Volunteers)","enrollment":165},{"nctId":"NCT04498832","phase":"PHASE3","title":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-10-21","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":2100},{"nctId":"NCT05779020","phase":"PHASE3","title":"Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children .","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2023-04-25","conditions":"Influenza, Human","enrollment":1373},{"nctId":"NCT04137887","phase":"PHASE3","title":"Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-11-04","conditions":"Influenza (Healthy Volunteers)","enrollment":33096},{"nctId":"NCT04210349","phase":"PHASE3","title":"Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-01-09","conditions":"Influenza","enrollment":7106},{"nctId":"NCT05426174","phase":"PHASE1","title":"Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-06-09","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":233},{"nctId":"NCT06095947","phase":"","title":"Exploration on the Quadrivalent Influenza Vaccine Immunization Schedule for Children Aged 3-8 Years","status":"COMPLETED","sponsor":"Hualan Biological Bacterin Co. Ltd.","startDate":"2021-09-15","conditions":"GCP","enrollment":652},{"nctId":"NCT05517174","phase":"PHASE4","title":"A Pragmatic Randomized Trial to Evaluate the Effectiveness of High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in Older Adults","status":"COMPLETED","sponsor":"Tor Biering-Sørensen","startDate":"2022-09-22","conditions":"Influenza","enrollment":332438},{"nctId":"NCT04551677","phase":"PHASE4","title":"Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-09-16","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":90},{"nctId":"NCT04109222","phase":"PHASE4","title":"Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-09-30","conditions":"Influenza","enrollment":90},{"nctId":"NCT05050318","phase":"PHASE4","title":"Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-09-08","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":90},{"nctId":"NCT06506812","phase":"PHASE4","title":"Pooled Analysis of Methodologically Harmonized Pragmatic Randomized Trials of High-Dose vs. Standard-Dose Influenza Vaccine Against Severe Clinical Outcomes","status":"COMPLETED","sponsor":"Tor Biering-Sørensen","startDate":"2025-05-31","conditions":"Influenza","enrollment":466320},{"nctId":"NCT04969276","phase":"PHASE2","title":"Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-07-16","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":306},{"nctId":"NCT04024228","phase":"PHASE3","title":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-10-28","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":1539},{"nctId":"NCT05144945","phase":"PHASE3","title":"Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-12-07","conditions":"Influenza (Healthy Volunteers)","enrollment":301},{"nctId":"NCT06907667","phase":"NA","title":"Study of the Impact of Time of Vaccination on Response to Influenza Vaccine in Patients With Chronic Renal Failure","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2025-09-03","conditions":"Vaccination; Infection","enrollment":735},{"nctId":"NCT06602024","phase":"PHASE3","title":"A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-09-16","conditions":"Seasonal Influenza","enrollment":40817},{"nctId":"NCT05513391","phase":"PHASE3","title":"Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-11-10","conditions":"Influenza Immunization","enrollment":366},{"nctId":"NCT03315975","phase":"PHASE4","title":"Flu Vaccine Responses in the Setting of Melanoma Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2017-10-20","conditions":"Viral Vaccines","enrollment":40},{"nctId":"NCT03346772","phase":"PHASE4","title":"Study of Immune Responses to Influenza Vaccination","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2017-10-20","conditions":"Influenza Vaccination","enrollment":75},{"nctId":"NCT06049927","phase":"PHASE3","title":"A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-09-16","conditions":"Seasonal Influenza","enrollment":3300},{"nctId":"NCT06141655","phase":"PHASE4","title":"HD vs SD Quadrivalent Influenza Vaccine in Adults Aged 65 to 79 Years in Galicia","status":"COMPLETED","sponsor":"Federico Martinón Torres","startDate":"2023-10-26","conditions":"Influenza","enrollment":134476},{"nctId":"NCT02783170","phase":"PHASE4","title":"Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women","status":"COMPLETED","sponsor":"Duke University","startDate":"2016-09","conditions":"Pregnancy","enrollment":81},{"nctId":"NCT05596734","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2022-10-28","conditions":"Influenza, Human, COVID-19","enrollment":1019},{"nctId":"NCT05801978","phase":"PHASE4","title":"Durability of Vaccine Responses","status":"RECRUITING","sponsor":"Emory University","startDate":"2023-04-11","conditions":"Vaccine Response","enrollment":66},{"nctId":"NCT06097273","phase":"PHASE3","title":"A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-10-19","conditions":"SARS-CoV-2, Influenza","enrollment":8061},{"nctId":"NCT06361875","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-04-01","conditions":"Influenza Immunization","enrollment":910},{"nctId":"NCT06744205","phase":"PHASE1, PHASE2","title":"A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2025-01-06","conditions":"Influenza, Healthy Volunteers","enrollment":1162},{"nctId":"NCT06054269","phase":"PHASE3","title":"Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2022-11-04","conditions":"Influenza","enrollment":192},{"nctId":"NCT05585983","phase":"PHASE4","title":"INfluenza VaccInation To Mitigate typE 1 Diabetes","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2022-12-14","conditions":"Diabetes Mellitus, Type 1","enrollment":100},{"nctId":"NCT05540522","phase":"PHASE3","title":"A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-09-12","conditions":"Influenza, Human","enrollment":45789},{"nctId":"NCT06015282","phase":"PHASE3","title":"The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"Seqirus","startDate":"2023-11-03","conditions":"Influenza, Human","enrollment":7741},{"nctId":"NCT06134804","phase":"PHASE3","title":"A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-10-24","conditions":"Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention","enrollment":959},{"nctId":"NCT04896086","phase":"PHASE1","title":"First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-05-24","conditions":"Influenza, Seasonal Influenza","enrollment":63},{"nctId":"NCT05648357","phase":"PHASE4","title":"A Study to Assess the Safety and Immune Response of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-12-14","conditions":"Influenza, Human","enrollment":250},{"nctId":"NCT06059456","phase":"","title":"Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24","status":"COMPLETED","sponsor":"Sanofi","startDate":"2023-10-02","conditions":"Influenza Immunization (Healthy Volunteers)","enrollment":2078},{"nctId":"NCT05947071","phase":"PHASE2","title":"High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-09-26","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":312},{"nctId":"NCT05650554","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-12-12","conditions":"Influenza Immunization","enrollment":682},{"nctId":"NCT05624606","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-11-28","conditions":"Influenza Immunization","enrollment":682},{"nctId":"NCT03932682","phase":"PHASE3","title":"Efficacy Study With QIVc in Pediatric Subjects","status":"COMPLETED","sponsor":"Seqirus","startDate":"2019-05-13","conditions":"Influenza, Human","enrollment":5723},{"nctId":"NCT03927131","phase":"PHASE3","title":"Safety and Immunogenicity of the Butantan Quadrivalent Influenza Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2021-05-12","conditions":"Influenza, Human","enrollment":5822},{"nctId":"NCT06342349","phase":"PHASE1","title":"A Clinical Trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) for Individuals Aged 6 Months and Above.","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2024-03-30","conditions":"Influenza","enrollment":300},{"nctId":"NCT03888989","phase":"PHASE1","title":"Response to Influenza Vaccine During Pregnancy","status":"TERMINATED","sponsor":"Stanford University","startDate":"2019-09-30","conditions":"Influenza","enrollment":2},{"nctId":"NCT06827873","phase":"NA","title":"Effect of Oral Supplements for Influenza Vaccine Response","status":"NOT_YET_RECRUITING","sponsor":"Tsinghua University","startDate":"2025-02","conditions":"Influenza Vaccine Response","enrollment":45},{"nctId":"NCT03753347","phase":"PHASE4","title":"TITRE III: Influenza B Immunogenicity Investigation","status":"ACTIVE_NOT_RECRUITING","sponsor":"British Columbia Centre for Disease Control","startDate":"2018-12-01","conditions":"Influenza","enrollment":55},{"nctId":"NCT06800950","phase":"PHASE3","title":"Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2025-02-08","conditions":"Influenza, Human, Influenza, Human Prevention, Influenza a","enrollment":4400},{"nctId":"NCT06622590","phase":"PHASE1","title":"Phase I Clinical Trial of Quadrivalent Influenza Virus Split Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2024-10-13","conditions":"Influenza, Human, Influenza a, Influenza Type B","enrollment":180},{"nctId":"NCT05553301","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-10-03","conditions":"Influenza Immunization","enrollment":560},{"nctId":"NCT05886777","phase":"PHASE2","title":"A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-06-05","conditions":"Healthy Participants","enrollment":1142},{"nctId":"NCT03312699","phase":"PHASE1","title":"Effects of Aging on Primary and Secondary Vaccine Responses","status":"COMPLETED","sponsor":"Stanford University","startDate":"2017-09-19","conditions":"Influenza, Hepatitis A, Typhoid","enrollment":54},{"nctId":"NCT03179761","phase":"PHASE2","title":"High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients","status":"COMPLETED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2017-10-09","conditions":"Hematopoietic Cell Transplantation","enrollment":124},{"nctId":"NCT02871206","phase":"PHASE4","title":"Adjuvanted Inactivated Vaccine Versus Inactivated Influenza Vaccine in Hutterite Children","status":"COMPLETED","sponsor":"McMaster University","startDate":"2016-11","conditions":"Influenza","enrollment":3425},{"nctId":"NCT03165981","phase":"PHASE4","title":"Fever After Simultaneous Versus Sequential Vaccination in Young Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-08-25","conditions":"Fever After Vaccination, Fever, Febrile Seizure","enrollment":221},{"nctId":"NCT03849560","phase":"PHASE2, PHASE3","title":"Safety, Reactogenicity, Immunogenicity, Efficacy of Influenza Vaccines Grippol® Quadri and Grippol® Plus in Volunteers","status":"COMPLETED","sponsor":"NPO Petrovax","startDate":"2016-11","conditions":"Influenza","enrollment":612},{"nctId":"NCT05284799","phase":"PHASE2","title":"Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.","status":"COMPLETED","sponsor":"Osivax","startDate":"2022-05-09","conditions":"Influenza","enrollment":180},{"nctId":"NCT02860039","phase":"PHASE2","title":"High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2016-09","conditions":"Hematopoietic Cell Transplantation Recipient, Malignant Neoplasm, Influenza","enrollment":170},{"nctId":"NCT04782323","phase":"PHASE2","title":"Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2021-04-13","conditions":"Influenza","enrollment":839},{"nctId":"NCT04667117","phase":"PHASE4","title":"A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-01-14","conditions":"Relapsing Multiple Sclerosis","enrollment":63},{"nctId":"NCT05568797","phase":"PHASE3","title":"A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-14","conditions":"Respiratory Syncytial Virus Infections","enrollment":1045},{"nctId":"NCT05559476","phase":"PHASE3","title":"A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-20","conditions":"Respiratory Syncytial Virus Infections","enrollment":1029},{"nctId":"NCT05858450","phase":"","title":"This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-05-05","conditions":"Influenza, Human, COVID-19","enrollment":3442996},{"nctId":"NCT03160118","phase":"PHASE4","title":"Study of Biomarkers of Immune Activation Associated with Symptoms and Immune Responses After Influenza Vaccination in Adults","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2017-03-27","conditions":"Prevention of Influenza","enrollment":20},{"nctId":"NCT04841577","phase":"PHASE3","title":"A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-04-27","conditions":"Respiratory Syncytial Virus Infections","enrollment":976},{"nctId":"NCT02936180","phase":"PHASE4","title":"Standard Versus High Dose Inactivated Influenza Vaccine in RA","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2016-10","conditions":"Rheumatoid Arthritis","enrollment":279},{"nctId":"NCT05007041","phase":"PHASE4","title":"Simultaneous RZV and aIIV4 Vaccination","status":"COMPLETED","sponsor":"Duke University","startDate":"2021-09-21","conditions":"Pain, Quality of Life, Injection Site Reaction","enrollment":267},{"nctId":"NCT05431725","phase":"PHASE3","title":"Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-07-18","conditions":"Seasonal Influenza","enrollment":2202},{"nctId":"NCT05245552","phase":"PHASE3","title":"A Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-08-08","conditions":"Seasonal Influenza","enrollment":217},{"nctId":"NCT03615482","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-09-14","conditions":"Pneumococcal Infections","enrollment":1200},{"nctId":"NCT04576702","phase":"PHASE2","title":"Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2020-10-08","conditions":"Influenza, Human","enrollment":471},{"nctId":"NCT05501561","phase":"PHASE2","title":"Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2022-08-25","conditions":"Influenza, Human","enrollment":1056},{"nctId":"NCT05970887","phase":"PHASE4","title":"Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines","status":"COMPLETED","sponsor":"Catholic Kwandong University","startDate":"2022-10-12","conditions":"Immune Response, Safety","enrollment":154},{"nctId":"NCT05568979","phase":"","title":"Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2022/23","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-10-06","conditions":"Influenza (Healthy Volunteers)","enrollment":1001},{"nctId":"NCT05052697","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-09-13","conditions":"Influenza, Human","enrollment":1158}],"_emaApprovals":[{"date":"","name":"QIV","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"pubchemSID":"315492464"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":307,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 4","pmid":"41776120","title":"Cost-effectiveness analysis of influenza vaccination with high-dose vaccine versus standard-dose quadrivalent vaccine in older adults in Spain.","journal":"The European journal of health economics : HEPAC : health economics in prevention and care"},{"date":"2026 Dec","pmid":"41701031","title":"Safety and immunogenicity of an investigational mRNA-lipid nanoparticle-based monovalent influenza vaccine: Results from a phase 1, randomized, dose-escalation study.","journal":"Human vaccines & immunotherapeutics"},{"date":"2026 Feb","pmid":"41674034","title":"The Diagnostic Value of Mean Apparent Propagator-MRI in Dysthyroid Optic Neuropathy: A Quantitative Analysis of the Entire Visual Pathway.","journal":"CNS neuroscience & therapeutics"},{"date":"2026 Jan 8","pmid":"41600986","title":"Effectiveness of the Cell-Based Quadrivalent Influenza Vaccine (SKYCellflu(®) QIV) in Children and Adolescents: A Multicenter Test-Negative Case-Control Study in Korea.","journal":"Vaccines"},{"date":"2026 Jan 25","pmid":"41391373","title":"Immunogenicity and safety of inactivated quadrivalent influenza vaccines in children aged 6-35 months: A multi-center, randomized, double-blind, active-controlled clinical trial.","journal":"Vaccine"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Vaccine","firstApprovalDate":"","enrichmentLevel":5,"visitCount":9,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":18,"withResults":9},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:28:14.321330+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}